Zymeworks (ZYME)

• Market cap: $1.82B
• 1 day: 2.07%
• 5 days: 5.98%
• 1 month: 5.28%
• 3 months: -7.87%
• 6 months: 65.55%
• Year to date: -9.39%
• 1 year: 77.75%
• 5 years: -35.63%
• 10 years: 85.54%
• Sector: Healthcare
• Industry: Biotechnology

About: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Employees: 273